DRAP Gains Observer Status at International Council for Harmonization

Pakistan’s DRAP Recognized by International Council for Harmonization

The Drug Regulatory Authority of Pakistan (DRAP) has been officially nominated as an observer at the International Council for Harmonization (ICH), marking a historic achievement for the country’s pharmaceutical sector.

Event Details

• The decision was made during the ICH meeting held in Rio de Janeiro on June 2–3, 2026.
• The nomination places DRAP alongside leading global regulators, giving Pakistan a voice in international discussions on medicine safety and quality.

Government Response

Federal Minister for Health, Syed Mustafa Kamal, congratulated DRAP on this milestone, calling it a historic moment for Pakistan. He emphasized that ICH plays a critical role in ensuring the quality, safety, and efficacy of medicines worldwide, and Pakistan’s inclusion will help strengthen its regulatory framework.

Benefits for Pakistan

• Improved regulatory standards: Observer status allows DRAP to align with global best practices.
• Enhanced confidence: The move is expected to boost trust in Pakistan’s pharmaceutical system among international stakeholders.
• Capacity building: Participation in ICH discussions will help DRAP modernize its processes and adopt advanced regulatory tools.
• Global integration: Pakistan’s pharmaceutical industry will gain better access to international markets through harmonized standards.

Final Takeaway

DRAP’s observer status at ICH is a significant step forward for Pakistan’s healthcare governance. It not only strengthens the country’s regulatory credibility but also ensures that patients benefit from safer, higher-quality medicines. This achievement reflects Pakistan’s growing commitment to global health standards and international collaboration.